Clinical outcomes of meibomian gland probing combined with platelet-rich plasma in patients with meibomian gland dysfunction: a randomized controlled trial

Meibomian gland dysfunction (MGD) is a major cause of evaporative dry eye disease. Current treatments mainly focus on either relieving meibomian gland obstruction or controlling inflammation, but therapeutic outcomes in moderate-to-severe MGD remain limited. This study evaluates a novel combination therapy integrating meibomian gland probing (MGP) with autologous platelet-rich plasma (PRP) mesotherapy to simultaneously target ductal obstruction and inflammatory dysfunction. This study included 30 patients (60 eyes) with bilateral moderate-to-severe MGD who were randomly allocated to the treatment or control group. Both eyes received the intervention assigned at the participant level. The treatment group received MGP combined with PRP mesotherapy, whereas the control group received conventional medical therapy. The participant was the unit of analysis, and bilateral ocular measurements were averaged at each time point. The prospectively specified primary outcome was the change in OSDI score from baseline to week 4. Secondary outcomes included changes in LLT, NIBUT, TMH, meibum quality, ocular redness, and MGL. Within-group changes and between-group differences in changes from baseline were analyzed using parametric or nonparametric tests, as appropriate. The Holm method was applied to adjust for multiple comparisons among the secondary outcomes. Compared with baseline, patients in the treatment group showed significant improvements in OSDI score, lipid layer thickness (LLT), tear meniscus height (TMH), meibum quality score, and Noninvasive tear breakup time (NIBUT) (all P < 0.05). Compared with the control group, the treatment group achieved significantly greater improvements in OSDI, LLT, and meibum quality score at 4 weeks post-treatment (all P < 0.05). MGP combined with PRP mesotherapy demonstrated favorable short-term efficacy and safety in patients with moderate-to-severe MGD. By improving both subjective symptoms and objective clinical outcomes, this combined treatment may offer a promising alternative for patients with MGD. http://clinicaltrials.gov , ChiCTR2600128838 (retrospectively registered July 27, 2026).

Authors

Institutions

Publication Details

Journal
BMC Ophthalmology
Published
2026-11-16
DOI
https://doi.org/10.1186/s12886-026-05493-2
Primary Topic
Ocular Surface and Contact Lens
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical outcomes of meibomian gland probing combined with platelet-rich plasma in patients with meibomian gland dysfunction: a randomized controlled trial

Xue-Song Mi, Wen-Ting Qiu, Hao-Tian Ou
BMC Ophthalmology
Ocular Surface and Contact Lens
article

Clinical outcomes of meibomian gland probing combined with platelet-rich plasma in patients with meibomian gland dysfunction: a randomized controlled trial

Xue-Song Mi, Wen-Ting Qiu, Hao-Tian Ou
article en

Abstract

Meibomian gland dysfunction (MGD) is a major cause of evaporative dry eye disease. Current treatments mainly focus on either relieving meibomian gland obstruction or controlling inflammation, but therapeutic outcomes in moderate-to-severe MGD remain limited. This study evaluates a novel combination therapy integrating meibomian gland probing (MGP) with autologous platelet-rich plasma (PRP) mesotherapy to simultaneously target ductal obstruction and inflammatory dysfunction. This study included 30 patients (60 eyes) with bilateral moderate-to-severe MGD who were randomly allocated to the treatment or control group. Both eyes received the intervention assigned at the participant level. The treatment group received MGP combined with PRP mesotherapy, whereas the control group received conventional medical therapy. The participant was the unit of analysis, and bilateral ocular measurements were averaged at each time point. The prospectively specified primary outcome was the change in OSDI score from baseline to week 4. Secondary outcomes included changes in LLT, NIBUT, TMH, meibum quality, ocular redness, and MGL. Within-group changes and between-group differences in changes from baseline were analyzed using parametric or nonparametric tests, as appropriate. The Holm method was applied to adjust for multiple comparisons among the secondary outcomes. Compared with baseline, patients in the treatment group showed significant improvements in OSDI score, lipid layer thickness (LLT), tear meniscus height (TMH), meibum quality score, and Noninvasive tear breakup time (NIBUT) (all P < 0.05). Compared with the control group, the treatment group achieved significantly greater improvements in OSDI, LLT, and meibum quality score at 4 weeks post-treatment (all P < 0.05). MGP combined with PRP mesotherapy demonstrated favorable short-term efficacy and safety in patients with moderate-to-severe MGD. By improving both subjective symptoms and objective clinical outcomes, this combined treatment may offer a promising alternative for patients with MGD. http://clinicaltrials.gov , ChiCTR2600128838 (retrospectively registered July 27, 2026).

BMC Ophthalmology
Foshan Hospital of TCM (CN), Foshan Second People's Hospital (CN), First Affiliated Hospital of Jinan University (CN), South China University of Technology (CN)
National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province
Good health and well-being
Ocular Surface and Contact Lens
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon